Braveheart Bio
BRVE
20.39
+1.12
+5.81%
Braveheart Bio
US · BRVE
#2845 by market cap
Listed 2026
20.39
+1.12
+5.81%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Revenue annual, last 1 years
Income statement
| Line item | 2025 |
|---|---|
| Revenue | -- |
| Gross profit | -- |
| Selling & admin expenses | 3.02M |
| Research & development | 63.73M |
| Operating profit | -66.75M |
| Pretax profit | -66.05M |
| Tax | -- |
| Net profit | -66.05M |
| Basic EPS | -5 |
| Diluted EPS | -5.32 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 27.00K | 508.00K | 2.48M | 4.14M | 4.76M | 12.61M |
| Research & development | 354.00K | 58.78M | 4.50M | 10.91M | 11.13M | 17.54M |
| Operating profit | -381.00K | -59.29M | -6.98M | -15.05M | -15.88M | -30.15M |
| Pretax profit | -381.00K | -59.12M | -6.45M | -14.28M | -14.99M | -26.50M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -381.00K | -59.12M | -6.45M | -14.28M | -14.99M | -26.50M |
| Basic EPS | 0 | -1 | 0 | 0 | 0 | -1 |
| Diluted EPS | -0.01 | -1.38 | -0.10 | -0.33 | -0.30 | -0.51 |
Balance sheet
| Line item | 2025 |
|---|---|
| Total current assets | 89.28M |
| Cash & ST investments | 89.16M |
| Inventory | -- |
| Total assets | 89.35M |
| Total current liabilities | 5.24M |
| Short-term debt | -- |
| Long-term debt | -- |
| Total liabilities | 5,333,000.00 |
| Total equity | 84.02M |
| Retained earnings | -66.05M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Total current assets | -- | -- | 89.28M | 81.07M | 123.45M | 359.57M |
| Cash & ST investments | -- | -- | 89.16M | 80.58M | 122.83M | 349.27M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | -- | -- | 89.35M | 81.88M | 126.96M | 514.45M |
| Total current liabilities | -- | -- | 5.24M | 10.00M | 9.06M | 16.67M |
| Short-term debt | -- | -- | -- | 373.00K | 377.00K | 415.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | -- | -- | 5,333,000.00 | 10,385,000.00 | 9,342,000.00 | 16,848,000.00 |
| Total equity | -- | -- | 84.02M | 71.49M | 117.61M | 497.60M |
| Retained earnings | -- | -- | -66.05M | -80.33M | -95.91M | -122.40M |
Cash flow
| Line item | 2025 |
|---|---|
| Operating cash flow | -2.01M |
| Depreciation & amortization | -- |
| Free cash flow | -35.58M |
| Dividends paid | -- |
| Stock buybacks / issuance | 95.00K |
| Ending cash balance | 89.16M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Operating cash flow | 0 | -740.00K | -1.27M | -5.19M | -16.95M | -24.37M |
| Depreciation & amortization | 0 | 0 | -- | 2.00K | 3.00K | 3.00K |
| Free cash flow | 0 | -33.47M | -2.11M | -8.22M | -16.94M | -24.37M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 4.00K | 89.00K | -- | -- | 0 |
| Ending cash balance | 2.00K | 67.53M | 89.16M | 80.58M | 122.83M | 121.29M |
Returns & efficiency
| Line item | 2025 |
|---|---|
| ROE %i | -- |
| ROA %i | -73.93 |
| ROIC %i | -- |
| 5-year avg ROE %i | -- |
| EBIT margin %i | -- |
| FCF / sales %i | -- |
| Current ratioi | 17.03 |
| Quick ratioi | 17.01 |
| Debt / assetsi | -- |
| LT debt / equityi | -- |
| Interest coveragei | -- |
| Revenue CAGR (3Y) %i | -- |
| Net income CAGR (3Y) %i | -- |
| FCF CAGR (3Y) %i | -- |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -- | -13.23 |
| ROA %i | -- | -- | -73.93 | -97.99 | -77.55 | -12.80 |
| ROIC %i | -- | -- | -- | -- | -- | -14.40 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | -- | -- | 17.03 | 8.11 | 13.63 | 21.57 |
| Quick ratioi | -- | -- | 17.01 | 8.06 | 13.56 | 20.95 |
| Debt / assetsi | -- | -- | -- | 0.81 | 0.45 | 0.10 |
| LT debt / equityi | -- | -- | -- | -- | -- | 0.02 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Braveheart Bio discussion 0 comments